Skip to main content
. 2020 Dec 29;13(1):69. doi: 10.3390/cancers13010069

Figure 2.

Figure 2

Prevention of paclitaxel-induced peripheral neuropathy (PIPN) signs with fenofibrate diet treatment: Mice were treated with 0.2% or 0.4% fenofibrate diets for 4 weeks (before, during and after paclitaxel) (a). Motivation and locomotion were evaluated by the wheel running test at D7 (b). Mechanical and cold (c,d) hypersensitivity were tested at BL, D0, D7, D14 and D21 with the Von Frey and acetone tests, respectively. Sensory nerve conduction velocity was measured at D22 (e). Sensory nerve compound action potential amplitude was measured at D22 (f). Values are expressed as mean ± SEM. N = 12/group. Results were compared using two-way ANOVA (c,d) and one-way ANOVA (b,e,f) and post-hoc Tukey’s test (*: p < 0.05, **: p < 0.01 and ***: p < 0.001 vs. vehicle; (#: p < 0.05, ##: p < 0.01 and ###: p < 0.001 vs. paclitaxel group). BL = Baseline; D = day; Feno = Fenofibrate; Reg = Regular; PAC = paclitaxel; Veh = Vehicle. No sex differences were observed (data not shown).